WO2021260492A1 - Profil de maladie moléculaire et son utilisation pour la surveillance et le traitement de la polyarthrite rhumatoïde - Google Patents

Profil de maladie moléculaire et son utilisation pour la surveillance et le traitement de la polyarthrite rhumatoïde Download PDF

Info

Publication number
WO2021260492A1
WO2021260492A1 PCT/IB2021/055282 IB2021055282W WO2021260492A1 WO 2021260492 A1 WO2021260492 A1 WO 2021260492A1 IB 2021055282 W IB2021055282 W IB 2021055282W WO 2021260492 A1 WO2021260492 A1 WO 2021260492A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
score
subjects
therapy
crp
Prior art date
Application number
PCT/IB2021/055282
Other languages
English (en)
Inventor
Matthew J. LOZA
Keying Ma
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Priority to EP21740611.5A priority Critical patent/EP4172622A1/fr
Priority to US18/003,185 priority patent/US20230243822A1/en
Priority to CA3187812A priority patent/CA3187812A1/fr
Priority to AU2021296354A priority patent/AU2021296354A1/en
Priority to CN202180052336.0A priority patent/CN116018519A/zh
Priority to JP2022579780A priority patent/JP2023531985A/ja
Priority to KR1020237002877A priority patent/KR20230028506A/ko
Publication of WO2021260492A1 publication Critical patent/WO2021260492A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Sont ici décrits des biomarqueurs qui sont indicatifs de l'efficacité d'un traitement contre la polyarthrite rhumatoïde ou de la réactivité à un régime de traitement chez un sujet qui est traité pour la polyarthrite rhumatoïde. Sont également décrites des sondes capables de détecter les biomarqueurs et des procédés et des kits associés pour évaluer, surveiller et sélectionner un traitement contre la polyarthrite rhumatoïde.
PCT/IB2021/055282 2020-06-26 2021-06-15 Profil de maladie moléculaire et son utilisation pour la surveillance et le traitement de la polyarthrite rhumatoïde WO2021260492A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP21740611.5A EP4172622A1 (fr) 2020-06-26 2021-06-15 Profil de maladie moléculaire et son utilisation pour la surveillance et le traitement de la polyarthrite rhumatoïde
US18/003,185 US20230243822A1 (en) 2020-06-26 2021-06-15 Molecular disease profile and use thereof for monitoring and treating rheumataoid arthritis
CA3187812A CA3187812A1 (fr) 2020-06-26 2021-06-15 Profil de maladie moleculaire et son utilisation pour la surveillance et le traitement de la polyarthrite rhumatoide
AU2021296354A AU2021296354A1 (en) 2020-06-26 2021-06-15 Molecular disease profile and use thereof for monitoring and treating rheumatoid arthritis
CN202180052336.0A CN116018519A (zh) 2020-06-26 2021-06-15 分子疾病概况及其用于监测和治疗类风湿性关节炎的用途
JP2022579780A JP2023531985A (ja) 2020-06-26 2021-06-15 関節リウマチをモニタリング及び治療するための分子疾患プロファイル及びその使用
KR1020237002877A KR20230028506A (ko) 2020-06-26 2021-06-15 분자 질환 프로파일 및 류마티스 관절염을 모니터링하고 치료하기 위한 이의 용도

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044457P 2020-06-26 2020-06-26
US63/044,457 2020-06-26

Publications (1)

Publication Number Publication Date
WO2021260492A1 true WO2021260492A1 (fr) 2021-12-30

Family

ID=76891102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/055282 WO2021260492A1 (fr) 2020-06-26 2021-06-15 Profil de maladie moléculaire et son utilisation pour la surveillance et le traitement de la polyarthrite rhumatoïde

Country Status (8)

Country Link
US (1) US20230243822A1 (fr)
EP (1) EP4172622A1 (fr)
JP (1) JP2023531985A (fr)
KR (1) KR20230028506A (fr)
CN (1) CN116018519A (fr)
AU (1) AU2021296354A1 (fr)
CA (1) CA3187812A1 (fr)
WO (1) WO2021260492A1 (fr)

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
ALETAHA D ET AL., LANCET, vol. 389, no. 10075, 25 March 2017 (2017-03-25), pages 1206 - 1217
AM VAN GESTEL ET AL., ARTH. RHEUM., vol. 41, no. 10, 1998, pages 1845 - 1850
BOINI SGUILLEMIN F, ANN RHEUM DIS., vol. 60, 2001, pages 817 - 827
CHEERAN MC ET AL., J. VIROL., vol. 77, 2003, pages 4502 - 4515
COPE AP ET AL., NAT REV RHEUMATOL., vol. 14, no. 1, January 2018 (2018-01-01), pages 53 - 60
COX JD ET AL., LUNG CANCER, vol. 10, no. 1, March 1994 (1994-03-01), pages 161 - 6
D. ALETAHA ET AL., ARTH. RHEUM., vol. 52, no. 9, 2005, pages 2625 - 2636
D. VAN DER HEIJDE ET AL., ANN. RHEUM. DIS., vol. 49, no. 11, 1990, pages 916 - 920
DASGUPTA BIDISHA ET AL: "Distinct Baseline Serum Molecular Profile and Pharmacodynamic Effects of Sirukumab, an AntiIL-6 Cytokine Monoclonal Antibody, in Asian-Pacific Patients with Active Rheumatoid Arthritis Despite DMARD or Anti-Tnf Therapy Across Two Global Phase 3 Trials", MEETING: 2016 ACR/ARHP ANNUAL MEETING, 1 October 2016 (2016-10-01), pages 1 - 2, XP055838529, Retrieved from the Internet <URL:https://acrabstracts.org/abstract/distinct-baseline-serum-molecular-profile-and-pharmacodynamic-effects-of-sirukumab-an-anti-il-6-cytokine-monoclonal-antibody-in-asian-pacific-patients-with-active-rheumatoid-arthritis-despit/> [retrieved on 20210907] *
DT FELSON ET AL., ARTH. RHEUM., vol. 36, no. 6, 1993, pages 729 - 740
EJA KROOT ET AL., ARTH. RHEUM., vol. 43, no. 7, 2000, pages 1473 - 1477
F. WOLFE, J. RHEUM., vol. 24, 1997, pages 1477 - 1485
FC BREEDVELD ET AL., ARTH. RHEUM., vol. 54, no. 1, 2006, pages 26 - 37
GAO JM ET AL., ACTA PHARMACOL. SIN., vol. 30, 2009, pages 193 - 201
GENOVESE MC ET AL., J RHEUMATOL., vol. 42, no. 10, October 2015 (2015-10-01), pages 1752 - 60
H. MAKINEN ET AL., ANN. RHEUM. DIS., vol. 64, no. 10, 2005, pages 1410 - 1413
HARLOWLANE: "ANTIBODIES: A LABORATORY MANUAL", 1988, COLD SPRING HARBOR LABORATORY PRESS
JIANMEI WANG ET AL: "Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis : CRP and IL-6 and Clinical Response to TCZ in RA", ARTHRITIS CARE RESEARCH, vol. 68, no. 6, 26 May 2016 (2016-05-26), US, pages 882 - 885, XP055766790, ISSN: 2151-464X, DOI: 10.1002/acr.22765 *
JS SMOLEN ET AL., RHEUMATOLOGY (OXFORD, vol. 42, 2003, pages 244 - 257
KOKUBUN M ET AL: "Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 360, no. 1-2, 1 October 2005 (2005-10-01), pages 97 - 102, XP027648726, ISSN: 0009-8981, [retrieved on 20051001] *
L. GOSSEC ET AL., ANN. RHEUM. DIS., vol. 63, no. 6, 2004, pages 675 - 680
M. VAN LEEUWEN, BR. J. RHEUM., vol. 32, 1993, pages 9 - 13
MLL PREVOO ET AL., ARTH. RHEUM., vol. 38, no. 6, 1995, pages 795 - 798
NA KHAN ET AL., ACR/ARHP SCIENTIFIC MEETING, 2008
PAPPAS AD ET AL., BMC MUSCULOSKELET DISORD., vol. 15, 1 April 2014 (2014-04-01), pages 113
PM RIDKER ET AL., NEJM, vol. 342, no. 12, 2000, pages 836 - 843
R. MALLYA ET AL., J. RHEUM., vol. 9, no. 2, 1982, pages 224 - 228
SIKORSKA DOROTA ET AL: "Diagnostic value of salivary CRP and IL-6 in patients undergoing anti-TNF-alpha therapy for rheumatic disease", INFLAMMOPHARMACOLOGY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 26, no. 5, 24 July 2018 (2018-07-24), pages 1183 - 1188, XP036595680, ISSN: 0925-4692, [retrieved on 20180724], DOI: 10.1007/S10787-018-0515-8 *
SMIT MJ ET AL., BLOOD, vol. 102, 2003, pages 1959 - 1965
T. PINCUS ET AL., CLIN. EXP. RHEUM., vol. 22, no. 35, 2004, pages S50 - S56
TA PEARSON ET AL., CIRCULATION, vol. 107, no. 3, 2003, pages 499 - 511
TAKEUCHI T ET AL., ANN RHEUM DIS., vol. 76, no. 12, December 2017 (2017-12-01), pages 2001 - 2008
TAKEUCHI T ET AL., ARTHRITIS RES THER., vol. 20, no. 1, 7 March 2018 (2018-03-07), pages 42
TAYLOR PC ET AL., ANN RHEUM DIS., vol. 77, no. 5, May 2018 (2018-05-01), pages 658 - 666
TAYLOR PETER C ET AL: "FILGOTINIB, A SELECTIVE JANUS KINASE 1 (JAK1) INHIBITOR, MODULATES DISEASE-ASSOCIATED CYTOKINES IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS", ANNALS OF THE RHEUMATIC DISEASES, vol. 78, no. Supplement 2, 14 June 2019 (2019-06-14), GB, pages 736 - 736, XP055838810, ISSN: 1468-2060, Retrieved from the Internet <URL:https://ard.bmj.com/content/annrheumdis/78/Suppl_2/736.1.full.pdf> *
WEINBLATT ME ET AL., ANN RHEUM DIS., vol. 72, no. 3, March 2013 (2013-03-01), pages 381 - 9
WELLS G ET AL., ANN RHEUM DIS., vol. 68, no. 6, June 2009 (2009-06-01), pages 954 - 60
Z. NADAREISHVILI ET AL., ARTH. RHEUM., vol. 59, no. 8, 2008, pages 1090 - 1096

Also Published As

Publication number Publication date
AU2021296354A1 (en) 2023-02-02
KR20230028506A (ko) 2023-02-28
JP2023531985A (ja) 2023-07-26
US20230243822A1 (en) 2023-08-03
EP4172622A1 (fr) 2023-05-03
CA3187812A1 (fr) 2021-12-30
CN116018519A (zh) 2023-04-25

Similar Documents

Publication Publication Date Title
US9086418B2 (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
AU2014207321A1 (en) Anti-TNF and anti-IL17 combination therapy biomarkers for inflammatory disease
JP7261501B2 (ja) 炎症性腸疾患の処置を改善するための腸管バリア機能の評価
Bechman et al. A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis
JP2013213774A (ja) 結核検査用バイオマーカー
US20230243822A1 (en) Molecular disease profile and use thereof for monitoring and treating rheumataoid arthritis
US20220390466A1 (en) Biomarkers of early osteoarthritis
Hussein et al. Role of cartilage oligomeric matrix protein (COMP) as a prognostic biomarker in follow-up of early rheumatoid arthritis patients: Correlation to musculoskeletal ultrasonographic findings
BR112021015596A2 (pt) Distúrbios mediados pelo interferon tipo i
RU2815973C2 (ru) Нарушения, опосредованные интерфероном i типа
US11779643B2 (en) Methods and compositions for the treatment of an inflammatory bowel disease
US11674951B2 (en) Methods for identifying a treatment for rheumatoid arthritis
JP6306124B2 (ja) 結核検査用バイオマーカー
WO2023067186A1 (fr) Procédés de prédiction de la rémission stable de la rectocolite hémorragique
JP2021181890A (ja) 成人スチル病（ａｓｄ）を判定するためのバイオマーカー
CN118028453A (en) Application of CXCL1 and TNFRSF12A in AKI diagnosis
AU2013201969A1 (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
van de Sande et al. ven

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21740611

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3187812

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022579780

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021740611

Country of ref document: EP

Effective date: 20230126

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021296354

Country of ref document: AU

Date of ref document: 20210615

Kind code of ref document: A